18F-FDG PET/CT在甲状腺癌中的临床应用

甲状腺癌是最常见的内分泌肿瘤,其显像方法很多,但由于甲状腺癌生物学行为的多重性,不同的显像方法对其的诊断价值及生物学行为判断价值各有不同.目前,18F-FDG PET/CT显像对不同进展期的甲状腺癌临床判断价值显著,其最重要的临床应用在于病灶诊断、分期和再分期及对各种治疗的评价和预后判断.笔者主要就18F-FDG PET/CT显像在甲状腺癌中的临床应用进行综述.     

18F-FDG PET/CT在Castleman病中的临床应用价值

目的 评价18F-FDG PET/CT在Castleman病(CD)的临床分型、疗效评价及转化监测中的应用价值.方法 回顾性分析14例CD患者[年龄(45.64±14.30)岁,男、女各7例]的18F-FDGPET/CT影像表现(病灶数量、分布、SUVmax),比较不同临床分型、病理类型、病理转化患者的影像表现,并对4例化疗后复查18 F-FDG PET/CT患者的病灶影像学变化进行记录.数据比较采用Mann-Whitney及Kruskal-Wallis秩和检验.结果 12例病理未发生转化的CD患者,化疗前18 F-FDG PET/CT检查均有1个或多个淋巴结肿大且伴有葡萄糖代谢增高,SUVmax3.94± 1.44(1.9 ～ 6.8);临床类型为单中心(2/12)与多中心(10/12) CD的SUV max分别为4.55±3.18和3.82±1.14,差异无统计学意义(Z=0.22,P＞0.05);病理类型分别为透明血管型(4/12)、浆细胞型(6/12)、混合型(2/12) CD的SUVmax分别为3.56±0.96、4.73± 1.41和2.30±0.57,差异无统计学意义(x2=4.74,P＞0.05).4例(4/12)化疗后复查PET/CT的患者中,3例病灶完全消失,1例病灶缩小、代谢减低.2例(2/14)发生病理转化的患者,SUVmax10.85±2.05,高于未转化者(3.94±1.44;Z=-2.19,P＜0.05).结论 18F-FDGPET/CT对于指导CD的临床分型、评价化疗疗效和监测病理转化均有一定的应用价值.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

目的 探讨18F-脱氧葡萄糖(FDG)PET/CT显像在恶性胸膜间皮瘤(MPM)诊断中的临床价值及原发肿瘤病灶平均标准摄取值(SUVmax)对患者预后的判断价值.方法 回顾性总结17例2002-2008年临床疑诊MPM患者18F-FDG PET/CT显像资料,测量病灶的SUVmax.将病理检查及临床随访证实的MPM患者按照有无转移分为2组,测定每例患者原发肿瘤病灶的SUVmax,用受试者工作特征(ROC)曲线评价SUVmax对患者转移与否的诊断价值,判断预后.采用SPSS 11.0软件进行t检验.结果 经病理及随访结果证实MPM 12例,良性胸膜病变5例,二者的SUVmax分别为5.78±1.81和2.72±2.51,差异有统计学意义(t=2.8,P<0.05).全身18F-FDG PET/CT显像诊断MPM的灵敏度为100%(12/12),特异性为4/5,准确性为94%(16/17),18F-FDG PET/CT显像有7例MPM伴有骨和(或)淋巴结转移.SUVmaxROC曲线分析表明曲线下面积(AUC)为0.80.结论 全身18F-FDG PET/CT显像对于MPM的诊断有重要价值.原发肿瘤病灶SUVmax越高越易发生转移,预后越差.     

18F-FDG PET/CT在心脏肿瘤诊断中的临床应用

目的 研究18F-FDG PET/CT在心脏肿瘤诊断中的临床应用价值.方法 自2007年1月至2011年12月行全身18F-FDG PET/CT检查的8649例受检者中,诊断为心脏肿瘤者占0.16％(14/8649).对这14例患者进行回顾性分析,其中男11例,女3例;年龄46.9(35 ～68)岁.患者最终诊断以外科手术病理结果(5例)、肿瘤病史和临床随访结果(9例)为依据,分析18 F-FDG PET/CT诊断情况.结果 14例心脏肿瘤,18F-FDG PET/CT均作出准确定位和定性诊断.其中,转移性肿瘤11例,占78.6％ (11/14);原发恶性肿瘤2例,占14.3％ (2/14);原发良性黏液瘤1例,占7.1％ (1/14).11例转移性肿瘤的原发肿瘤分别为HCC(8例),肺癌(2例)和食管癌(1例).2例原发恶性肿瘤均发生转移.13例恶性肿瘤患者SUVmax为3.2 ～10.7,高于正常心肌.结论 全身18F-FDG PET/CT检查对心脏转移及原发肿瘤诊断有重要价值,可探查心脏恶性肿瘤全身转移情况,从而进行准确分期,指导临床治疗.     

^18F-FDG PET/CT在POEMS综合征诊断中的应用

目的 总结多发性周围神经病、脏器肿大、内分泌病变、M蛋白和皮肤病变（POEMS）综合征的18F-FDG PET/CT表现,探讨^18F-FDG PET/CT在该病中的应用价值.方法 2008年10月至2013年2月间经临床证实的11例POEMS综合征患者[男7例,女4例,年龄49～73（58.5±8.4）岁],确诊前均行^18F-FDG PET/CT显像.总结病例的PET/CT图像特征,观察病灶^18F-FDG摄取情况.结果 11例患者均存在多发硬化性骨病变（141个）：顶骨5个,肩胛骨8个,锁骨4个,肋骨16个,椎体64个,髂骨29个,坐骨6个,耻骨8个,肱骨1个;其中58个PET显像阳性,SUVmax为4.3±1.6.肝脏肿大者1例,脾脏肿大者3例,同时存在肝、脾肿大者2例;其中有3例肿大脾脏FDG摄取增高,SUVmax为3.2～4.1.5例患者多发淋巴结肿大,均可见FDG摄取增高,SUVmax为2.6～4.9.胸腔积液者1例,腹腔积液者3例,盆腔积液者3例,三者并存2例,且这2例合并存在皮下水肿,均未见异常^18F-FDG摄取.结论 ^18F-FDG PET/CT可以同时发现POEMS综合征的骨损害、脏器肿大以及血管外水容量过负荷等多系统病变,其表现具有一定的特征性,能为临床进一步诊治提供依据.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

Objective Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with median survival of 4- 12 months. The aim of this study was to evaluate the clinic value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the diagno-sis and to staging of MPM and to determine if the mean standardized uptake value (SUVmax) of primary tumor correlates with staging and prognosis. Methods Study was conducted retrospectively including 17 pa-tients with clinical suspicion of MPM from 2002 to 2008. Twelve cases of MPM and 5 cases benign pleural pa-thology were proven by histopathology and clinical follow-up. 18F-FDG PET/CT imaging was performed 1 h af-ter injection of 7.4 MBq/kg 18F-FDG. Patients with MPM confirmed by histopatholagy were divided into two groups: with and without metastasis. PET/CT findings were analyzed to determine if SUVmax of primary tumor correlates with staging and prognosis. Receiver operating characteristic (ROC) curve of SUVmax of primary tumor was evaluated to determine if it was a predictor of metastasis and survival time. Results The difference in SUVmax between MPM and benign pleural were statistical significant (5.78±1.81 vs 2.72± 2.51, t = 2. 8, P < 0.05). The diagnostic sensitivity, specificity and accuracy of 18F-FDG PET/CT imaging for MPM were 100% (12/12) , 4/5 and 94% (16/17). All 7 cases of bone and lymph node metastases were detected by 18F-FDG PET/CT imaging. Area under the curve (AUC) was 0.80. Conclusions 18F-FDG PET/CT imaging is useful in the diagnosis and staging of MPM. High SUVmax in the primary tumor correlates well with prognosis and predication of a greater propensity to have nodal and distant metastasis.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

Objective Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with median survival of 4- 12 months. The aim of this study was to evaluate the clinic value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the diagno-sis and to staging of MPM and to determine if the mean standardized uptake value (SUVmax) of primary tumor correlates with staging and prognosis. Methods Study was conducted retrospectively including 17 pa-tients with clinical suspicion of MPM from 2002 to 2008. Twelve cases of MPM and 5 cases benign pleural pa-thology were proven by histopathology and clinical follow-up. 18F-FDG PET/CT imaging was performed 1 h af-ter injection of 7.4 MBq/kg 18F-FDG. Patients with MPM confirmed by histopatholagy were divided into two groups: with and without metastasis. PET/CT findings were analyzed to determine if SUVmax of primary tumor correlates with staging and prognosis. Receiver operating characteristic (ROC) curve of SUVmax of primary tumor was evaluated to determine if it was a predictor of metastasis and survival time. Results The difference in SUVmax between MPM and benign pleural were statistical significant (5.78±1.81 vs 2.72± 2.51, t = 2. 8, P < 0.05). The diagnostic sensitivity, specificity and accuracy of 18F-FDG PET/CT imaging for MPM were 100% (12/12) , 4/5 and 94% (16/17). All 7 cases of bone and lymph node metastases were detected by 18F-FDG PET/CT imaging. Area under the curve (AUC) was 0.80. Conclusions 18F-FDG PET/CT imaging is useful in the diagnosis and staging of MPM. High SUVmax in the primary tumor correlates well with prognosis and predication of a greater propensity to have nodal and distant metastasis.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

Objective Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with median survival of 4- 12 months. The aim of this study was to evaluate the clinic value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the diagno-sis and to staging of MPM and to determine if the mean standardized uptake value (SUVmax) of primary tumor correlates with staging and prognosis. Methods Study was conducted retrospectively including 17 pa-tients with clinical suspicion of MPM from 2002 to 2008. Twelve cases of MPM and 5 cases benign pleural pa-thology were proven by histopathology and clinical follow-up. 18F-FDG PET/CT imaging was performed 1 h af-ter injection of 7.4 MBq/kg 18F-FDG. Patients with MPM confirmed by histopatholagy were divided into two groups: with and without metastasis. PET/CT findings were analyzed to determine if SUVmax of primary tumor correlates with staging and prognosis. Receiver operating characteristic (ROC) curve of SUVmax of primary tumor was evaluated to determine if it was a predictor of metastasis and survival time. Results The difference in SUVmax between MPM and benign pleural were statistical significant (5.78±1.81 vs 2.72± 2.51, t = 2. 8, P < 0.05). The diagnostic sensitivity, specificity and accuracy of 18F-FDG PET/CT imaging for MPM were 100% (12/12) , 4/5 and 94% (16/17). All 7 cases of bone and lymph node metastases were detected by 18F-FDG PET/CT imaging. Area under the curve (AUC) was 0.80. Conclusions 18F-FDG PET/CT imaging is useful in the diagnosis and staging of MPM. High SUVmax in the primary tumor correlates well with prognosis and predication of a greater propensity to have nodal and distant metastasis.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

Objective Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with median survival of 4- 12 months. The aim of this study was to evaluate the clinic value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the diagno-sis and to staging of MPM and to determine if the mean standardized uptake value (SUVmax) of primary tumor correlates with staging and prognosis. Methods Study was conducted retrospectively including 17 pa-tients with clinical suspicion of MPM from 2002 to 2008. Twelve cases of MPM and 5 cases benign pleural pa-thology were proven by histopathology and clinical follow-up. 18F-FDG PET/CT imaging was performed 1 h af-ter injection of 7.4 MBq/kg 18F-FDG. Patients with MPM confirmed by histopatholagy were divided into two groups: with and without metastasis. PET/CT findings were analyzed to determine if SUVmax of primary tumor correlates with staging and prognosis. Receiver operating characteristic (ROC) curve of SUVmax of primary tumor was evaluated to determine if it was a predictor of metastasis and survival time. Results The difference in SUVmax between MPM and benign pleural were statistical significant (5.78±1.81 vs 2.72± 2.51, t = 2. 8, P < 0.05). The diagnostic sensitivity, specificity and accuracy of 18F-FDG PET/CT imaging for MPM were 100% (12/12) , 4/5 and 94% (16/17). All 7 cases of bone and lymph node metastases were detected by 18F-FDG PET/CT imaging. Area under the curve (AUC) was 0.80. Conclusions 18F-FDG PET/CT imaging is useful in the diagnosis and staging of MPM. High SUVmax in the primary tumor correlates well with prognosis and predication of a greater propensity to have nodal and distant metastasis.     

18F-FDG PET/CT显像在恶性胸膜间皮瘤诊断中的价值

Objective Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with median survival of 4- 12 months. The aim of this study was to evaluate the clinic value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the diagno-sis and to staging of MPM and to determine if the mean standardized uptake value (SUVmax) of primary tumor correlates with staging and prognosis. Methods Study was conducted retrospectively including 17 pa-tients with clinical suspicion of MPM from 2002 to 2008. Twelve cases of MPM and 5 cases benign pleural pa-thology were proven by histopathology and clinical follow-up. 18F-FDG PET/CT imaging was performed 1 h af-ter injection of 7.4 MBq/kg 18F-FDG. Patients with MPM confirmed by histopatholagy were divided into two groups: with and without metastasis. PET/CT findings were analyzed to determine if SUVmax of primary tumor correlates with staging and prognosis. Receiver operating characteristic (ROC) curve of SUVmax of primary tumor was evaluated to determine if it was a predictor of metastasis and survival time. Results The difference in SUVmax between MPM and benign pleural were statistical significant (5.78±1.81 vs 2.72± 2.51, t = 2. 8, P < 0.05). The diagnostic sensitivity, specificity and accuracy of 18F-FDG PET/CT imaging for MPM were 100% (12/12) , 4/5 and 94% (16/17). All 7 cases of bone and lymph node metastases were detected by 18F-FDG PET/CT imaging. Area under the curve (AUC) was 0.80. Conclusions 18F-FDG PET/CT imaging is useful in the diagnosis and staging of MPM. High SUVmax in the primary tumor correlates well with prognosis and predication of a greater propensity to have nodal and distant metastasis.     

18F-FDG PET/CT对甲状腺结节性病变的诊断价值

目的 探讨18F-FDG PET/CT显像对于甲状腺结节性病变的诊断价值.方法 回顾性分析2008年1月至2012年5月18F-FDG PET/CT检查发现甲状腺结节性病变并有病理结果的34例患者资料,其中男13例,女21例,年龄21 ～ 73(53.00± 12.57)岁.选取20名2011年1月至2011年12月在PET/CT中心进行健康体格检查而甲状腺未发现异常者作为健康对照组,其中男9名,女11名,年龄40～55(45.00±4.72)岁.应用Wilcoxon秩和检验,分别对甲状腺良性病变和恶性病变组、良性病变和对照组及恶性病变和对照组的SUVmax进行分析,比较差异并对甲状腺结节长径行ROC曲线分析(AUC≥0.70为诊断准确性中～较高).甲状腺结节出现局限性异常放射性浓聚,而CT示病灶边界不清,内部密度不均,有点状、小圆形或弧形钙化,或同时颈部出现异常放射性浓聚的肿大淋巴结,远处器官出现可疑转移瘤者,PET/CT诊断为恶性.计算PET/CT诊断甲状腺恶性结节的效能指标.结果 (1)病理结果为恶性肿瘤18例,良性病变16例.甲状腺良、恶性组和健康对照组SUVmax分别为7.59±8.69、5.75±4.48和1.38±0.57.甲状腺良、恶性组SUVmax差异无统计学意义(u=0.207,P＞0.05),但两者与健康对照组比较差异均有统计学意义(u=3.408和3.553,均P＜0.01).(2)甲状腺良、恶性组SUVmax的ROC分析,AUC为0.557 (＜0.70),诊断准确性较低.(3)18F-FDG PET/CT诊断甲状腺良、恶性结节的灵敏度、特异性、阳性预测值、阴性预测值和准确性分别为72.2％(13/18)、75.0％(12/16)、76.5％(13/17)、70.6％(12/17)和73.5％ (25/34).结论 甲状腺结节单纯依据放射性摄取情况判断良恶性价值有限,但结合同机CT上的病灶形态学特点,18F-FDG PET/CT可以初步推测其良恶性,为临床提供客观信息.     

^18F-FDG PET／CT在胰腺癌诊断中的价值

目的评价^18F-脱氧葡萄糖（FDG）PET／CT鉴别诊断胰腺良恶性病变及检测淋巴结和（或）远处转移的价值。方法回顾性分析上海交通大学医学院附属仁济医院行^18F—FDGPET／CT检查的46例临床疑胰腺肿瘤患者的影像学检查资料和临床资料,其中胰腺癌患者26例,良性病变者20例,比较分析PET和CT的特征。结果当选择最大标准摄取值（SUVmax）=2．95为判断良恶性的界值时,对胰腺癌诊断的灵敏度是88．5％（23／26）,特异性是85．0％（17／20）。^18F—FDGPET／CT显像假阳性3例,假阴性3例。同时发现16例检查前未确定的肝、肺、骨及淋巴结转移患者。根据显像结果,11例患者治疗方案得以修正。结论根据现有资料分析,^18F—FDGPET／CT是鉴别诊断胰腺良恶性病变及检测胰腺癌患者淋巴结和（或）远处转移一种较好的方法。     

18F-FDG PET/CT显像对脊柱单发转移瘤的诊断价值

目的 评价18F-FDG PET/CT显像对脊柱单发转移瘤的诊断效能及优势.方法 回顾性分析67例[男41例,女26例,年龄40～83(61.5 ±10.2)岁]有恶性肿瘤病史且经局部CT和(或)MRI检查发现单个椎体病变,疑为骨转移瘤患者的资料.患者均行PET/CT显像,既往未行MRI检查者于PET/CT检查后1周内行病变椎体MRI检查.脊柱单发病灶以病理学诊断或6个月以上影像学及临床随访作为最终诊断依据,将PET/CT融合图像与单纯PET、CT及MRI图像分别对比,评价PET/CT显像对脊柱单发转移瘤的诊断效能及优势.对数据行x2检验.结果 PET/CT显像诊断脊柱单发转移瘤的灵敏度为96.3％(52/54),特异性为84.6％ (11/13),阳性预测值为96.3％(52/54),阴性预测值为84.6％ (11/13),准确性为94.0％(63/67).灵敏度、阴性预测值及准确性与PET[81.5％ (44/54)、44.4％ (8/18)、77.6％(52/67)]相比差异均有统计学意义(x2值分别为6.000、5.134、7.421,均P＜0.05);灵敏度、特异性、阴性预测值、准确性与CT[79.6％(43/54)、53.8％ (7/13)、38.9％(7/18)、74.6％(50/67)]相比差异有统计学意义(,值分别为7.083、4.248、6.482、9.543,均P＜0.05);准确性与MRI[80.6％ (54/67)]相比差异有统计学意义(x2=5.457,P＜0.05).结论 PET/CT对脊柱单发转移瘤有较高的诊断效能及优势.PET/CT准确性高于MRI,当在MRI怀疑脊柱单发转移难以明确性质时,可以通过PET/CT提高诊断准确性.     

18F-FDG PET/CT在恶性肿瘤伽玛刀治疗后复查中的应用

目的探讨18F-脱氧葡萄糖(FDG)PET/CT在恶性肿瘤伽玛刀治疗后疗效评价中的应用价值.方法对18例体部恶性肿瘤伽玛刀治疗前后行PET/CT检查的患者资料进行分析,观察病灶的CT及PET影像学表现,进行治疗前后疗效对比分析.结果治疗有效的CT检查表现为病灶缩小、纤维化,大病灶中心低密度液化坏死区,有斑片状钙化.CT检查疗效分析结果治疗后18例中完全缓解(CR)3例(16.7%),部分缓解(PR)10例(55.6%),无变化(NC)2例(11.1%),进展(PD)3例(16.7%),总缓解率(CR+PR)为72.2%.共34个病灶进行治疗,治疗后有效病灶PET显像表现为放射性浓聚程度较轻,较模糊,边缘欠清,分布不均,坏死区见放射性缺损.PET显像疗效分析结果治疗后18例中CR4例(22.2%),PR 8例(44.4%),NC 1例(5.6%),PD 5例(27.8%),CR+PR为66.7%.治疗后标准摄取值(SUV)改变的病灶为100%(34/34例),其中SUV下降病灶占85.3%(29/34个),SUV增加病灶占14.7%(5/34个).SUV变化率＞50%的病灶占44.1%(15/34个).34个病灶治疗前后SUV分别为6.33±2.62、3.88±1.82,两者比较差异有显著性(t=5.580,P＜0.001).结论 PET/CT对伽玛刀治疗后肿瘤局部控制率的评价有重要价值.PET显示肿瘤残余及复发明显优于CT.     

18F-FDG PET/CT对肾脏肿瘤的诊断价值

目的 探讨18F-FDG PET/CT对肾脏肿瘤的临床诊断价值.方法 回顾性分析近5年经18 F-FDG PET/CT诊断为肾脏肿瘤且病理或临床综合诊断明确的79例患者资料,其中男52例,女27例,平均年龄(57.3±14.1)岁.PET/CT诊断根据肾脏轮廓改变、病灶密度异常及FDG摄取程度做出.计算18F-FDG PET/CT诊断肾脏肿瘤的效能指标.结果 79例中恶性肿瘤70例(包括肾细胞癌40例、肾盂癌5例,淋巴瘤8例,转移瘤16例,肾筋膜囊脂肪肉瘤1例);良性肿瘤9例(包括血管平滑肌脂肪瘤7例,肾嗜酸细胞腺瘤1例,后肾腺瘤1例;不含小脂滴样错构瘤病例).18 F-FDG PET/CT对病灶检出率达97.5％(77/79),对肾脏良恶性病灶判断的灵敏度为92.9％ (65/70),特异性为7/9,准确性为91.1％ (72/79),阳性预测值为97.0％(65/67),阴性预测值为58.3％ (7/12).结论 18 F-FDG PET/CT能够检出并判断大部分肾脏占位病变性质,对肾脏肿瘤患者进行全身检查并做出综合评价是18F-FDG PET/CT的优势之一.     

18F-FDG PET/CT对原发性腹膜乳头状浆液性癌的诊断价值

目的 探讨18F-FDG PET/CT显像在诊断原发性腹膜乳头状浆液性癌(PPPSC)中的价值.方法 回顾性分析2009年3月至2011年10月在PET/CT中心检查并经病理确诊的10例绝经期女性PPPSC患者,年龄61～81(69.4±6.2)岁.患者均行18F-FDG PET/CT显像,分析其病灶CT表现及PET的SUVmax,观察PPPSC的PET/CT表现,并与病理结果进行对比分析,同时测定PET/CT检查前或后1周内患者血清CA125,采用直线相关分析,评估壁腹膜、大网膜、肠系膜三者中最大的SUVmax与CA125的相关性.结果 10例PPPSC患者i8F-FDG PET/CT显像主要表现为:10例患者大网膜呈絮状、多发结节状及饼状软组织密度不均匀增高及代谢增强(SUVmax为6.32±2.87);9例壁腹膜及8例肠系膜呈弥漫性或局限性结节状或条状软组织不均匀增厚及代谢增强(SUVmax分别为5.96±2.14和5.70±1.69),其中壁腹膜以盆壁腹膜受累为主,肠系膜以小肠系膜受累为主;10例患者均有不同程度的腹腔积液,以肝周及盆腔为主;2例双侧卵巢及1例右侧卵巢稍增大,最大直径均在5 cm以内,同时伴有代谢异常增高;4例腹膜后淋巴结转移;出现点状钙化灶、有少量胸腔积液、有肝脏转移、伴有肝门淋巴结转移各2例.所有患者CA125均增高[(51.25±26.40)×104 U/L],CA125与壁腹膜、大网膜及肠系膜三者中最大SUVmax无明显相关性(r=0.05,P＞0.05).结论 PET/CT显像可显示PPPSC病灶部位,也能反映病灶的代谢状态,可用于PPPSC的辅助诊断.     

前列腺癌骨转移18F-FDG PET/CT临床应用分析

目的 分析前列腺癌骨转移的形态及脱氧葡萄糖(FDG)代谢特点,探讨PET/CT的临床应用价值.方法 回顾性分析27例依据影像、临床或组织病理诊断为前列腺癌骨转移患者的PET/CT资料,总结骨转移瘤的分布、数目、大小、密度及FDG摄取等特点,分析病变大小与最大标准化摄取值(SUVmax)的相关性.结果 27例中,弥漫性转移11例,其中10例PET与CT检出病灶数目大致相符,1例PET发现病灶明显多于CT;多发及单发转移16例,选择测量病变51个,大小平均(1.9±1.0)cm,SUVmax平均为6.5±3.7,二者呈正相关.48个病变代谢活跃,其中成骨性46个(3个病灶PET浓聚范围大于CT所示),溶骨性1个,1个病灶CT未显示;3个病灶代谢与周围骨质接近,其中1个为成骨性改变,另2个CT未显示.结论 PET/CT诊断前列腺癌骨转移的敏感性较高,可能会漏诊代谢不活跃的小病灶.     

18F-FDG PET/CT在鼻咽癌颈部淋巴结转移分期中的作用

目的 探讨18F-FDG PET/CT在鼻咽癌患者颈部淋巴结转移分期中的作用.方法 按前瞻性设计研究方案,纳入2009年3月至2010年11月病理确诊为鼻咽癌的初治患者62例,其中男48例,女14例,中位年龄43岁.患者放疗前1周内行CT或MRI检查并进行AJCC分期,然后行18FFDG PET/CT检查后再次分期.以治疗后随访6个月以上结果为标准,评价2种检查方法进行N分期的准确性.分析PET/CT N分期对治疗方案的影响,并计算Kappa值,进行一致性检验,率的比较采用x2检验.结果 62例患者中,N0 9例,N1 16例,N2 24例,N3 13例.18F-FDG PET/CT N分期准确性为96.8％(60/62),与实际N分期一致性检验Kappa值为0.955;CT或MRI N分期准确性为72.7％(45/62),Kappa值为0.607.30.6％(19/62)患者PET/CT与CT或MRI N分期不一致,随访证实PET/CT正确改变了27.4％(17/62)患者的N分期;其中l例从N0提高至N2,由根治性放疗改为放化疗综合治疗,另16例改变了转移淋巴结GTV的勾画和照射剂量.PET/CT咽后淋巴结检出率为54.8％(34/62),其灵敏度、特异性和准确性分别为80.0％ (20/25)、94.4％(17/18)和86.0％(37/43).比较43例同时有MRI和PET/CT检查结果的患者资料,两者对咽后淋巴结的检出率分别为60.5％(26/43)和55.8％ (24/43),差异无统计学意义(x2=2.000,P＞0.05).结论 18F-FDGPET/CT较常规CT或MRI对鼻咽癌N分期的准确性高,且能较好地显示咽后淋巴结,在定性较小淋巴结方面有一定优势.